tetano
Editor, Senior Moderator
Antiviral Res
. 2024 Jun 9:105924.
doi: 10.1016/j.antiviral.2024.105924. Online ahead of print. A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection
Guanxing Zhai[SUP] 1 [/SUP], Weihui Fu[SUP] 1 [/SUP], Songhua Yuan[SUP] 1 [/SUP], Peng Sun[SUP] 1 [/SUP], Cuisong Zhu[SUP] 1 [/SUP], Chen Zhao[SUP] 2 [/SUP], Xiaoyan Zhang[SUP] 3 [/SUP], Jianqing Xu[SUP] 4 [/SUP]
Affiliations
Human interferon α2 (IFNα2) is a cytokine with broad-spectrum antiviral activity, and its engineered forms are widely used to treat viral infections. However, IFNα2 may trigger proinflammatory responses and underlying side effects during treatment. Trefoil factor 2 (TFF2) is a secreted protein with anti-inflammatory properties. Here, we explored whether coupling IFNα2 to TFF2 in a two-in-one fusion form could combine the beneficial effects of both molecules on viral infections toward a more desirable treatment outcome. We engineered two forms of human IFNα2 and TFF2 fusion proteins, IFNα2-TFF2-Fc (ITF) and TFF2-IFNα2-Fc (TIF), and examined their properties in vitro in comparison to IFNα2 and TFF2 alone. RNA-Seq was further used to explore such comparison on dynamic gene regulation at transriptomic level. These in vitro assessments collectively indicated that TIF largely retained the antiviral activity of IFNα2 while being a weaker inflammation inducer, consistent with the presence of TFF2 activity. We further demonstrated the superiority of TIF over IFNα2 or TFF2 alone in treating influenza infection using a mouse infection model. Together, our study provided evidence supporting that, by possessing antiviral activity conferred by IFNα2 with complementation from TFF2 in suppressing the inflammatory side effects, the fusion proteins, particularly TIF, represent more effective agents against influenza and other respiratory viral infections than IFNα2 or TFF2 alone. It implies that merging two molecules with complementary functions holds potential for developing novel therapeutics against viral infections.
Keywords: H1N1 (PR8); IFNα2-TFF2 fusion protein; anti-inflammation; antiviral; mice protectivity.
. 2024 Jun 9:105924.
doi: 10.1016/j.antiviral.2024.105924. Online ahead of print. A fusion protein approach to integrate antiviral and anti-inflammatory activities for developing new therapeutics against influenza A virus infection
Guanxing Zhai[SUP] 1 [/SUP], Weihui Fu[SUP] 1 [/SUP], Songhua Yuan[SUP] 1 [/SUP], Peng Sun[SUP] 1 [/SUP], Cuisong Zhu[SUP] 1 [/SUP], Chen Zhao[SUP] 2 [/SUP], Xiaoyan Zhang[SUP] 3 [/SUP], Jianqing Xu[SUP] 4 [/SUP]
Affiliations
- PMID: 38862076
- DOI: 10.1016/j.antiviral.2024.105924
Human interferon α2 (IFNα2) is a cytokine with broad-spectrum antiviral activity, and its engineered forms are widely used to treat viral infections. However, IFNα2 may trigger proinflammatory responses and underlying side effects during treatment. Trefoil factor 2 (TFF2) is a secreted protein with anti-inflammatory properties. Here, we explored whether coupling IFNα2 to TFF2 in a two-in-one fusion form could combine the beneficial effects of both molecules on viral infections toward a more desirable treatment outcome. We engineered two forms of human IFNα2 and TFF2 fusion proteins, IFNα2-TFF2-Fc (ITF) and TFF2-IFNα2-Fc (TIF), and examined their properties in vitro in comparison to IFNα2 and TFF2 alone. RNA-Seq was further used to explore such comparison on dynamic gene regulation at transriptomic level. These in vitro assessments collectively indicated that TIF largely retained the antiviral activity of IFNα2 while being a weaker inflammation inducer, consistent with the presence of TFF2 activity. We further demonstrated the superiority of TIF over IFNα2 or TFF2 alone in treating influenza infection using a mouse infection model. Together, our study provided evidence supporting that, by possessing antiviral activity conferred by IFNα2 with complementation from TFF2 in suppressing the inflammatory side effects, the fusion proteins, particularly TIF, represent more effective agents against influenza and other respiratory viral infections than IFNα2 or TFF2 alone. It implies that merging two molecules with complementary functions holds potential for developing novel therapeutics against viral infections.
Keywords: H1N1 (PR8); IFNα2-TFF2 fusion protein; anti-inflammation; antiviral; mice protectivity.